Search
for
Sort by
Research 421–450 of 929
- Advances in Topical Therapies for Clinically Relevant and Prevalent Forms of Alopecia
- Wigs and Alopecia Areata: Psychosocial Impact and Economic Considerations
- Evaluation of the Efficacy and Safety of Oral Tofacitinib for the Treatment of Alopecia Areata in Children
- Treatment of moderate-to-severe alopecia areata in adolescents with baricitinib: A retrospective review of 29 patients
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
- Switching JAK inhibitors: evaluating baricitinib’s effectiveness in alopecia areata after tofacitinib failure
- Efficacy of Janus Kinase Inhibitors in Alopecia in Jordanian Patients: A Retrospective Cohort Study
- Evaluating Current and Emergent JAK Inhibitors for Alopecia Areata: A Narrative Review
- Androgenetic Alopecia: Therapy Update
- Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata
- Frontal Fibrosing Alopecia: An Update on Pathogenesis, Diagnosis, and Treatment
- Permanent chemotherapy-induced alopecia after hematopoietic stem cell transplantation treated with low-dose oral minoxidil
- Update on Frontal Fibrosing Alopecia
- Recurring Chemotherapy-Associated Alopecia Areata: Case Report and Literature Review
- Alopecia Areata
- Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
- Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata
- Pathogenesis and treatment options for chemotherapy‐induced alopecia: a systematic review
- The potential of androgenic alopecia management from plant derivatives
- <i>DSG4</i> Gene Variants as a Cause of Hypotrichosis in the Child with Severe Atopic Dermatitis: Clinical Case
- Male pattern baldness: current treatments, future prospects
- Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata
- A falling out following minoxidil: Telogen effluvium
- New drugs under investigation for the treatment of alopecias
- Treatment of Alopecia Areata with Oral JAK Inhibitor : Focusing on Clinical Outcomes with Baricitinib
- The use of phosphodiesterase inhibitors for the treatment of alopecia
- Aesthetic medicine treatments for oncology patients — a narrative literature review
- Degree of Alignment Between Japanese Patients and Physicians on Alopecia Areata Disease Severity and Treatment Satisfaction: A Real-World Survey
- Criteria for Commencing and Continuing Subsidised Janus Kinase Inhibitor Therapy in Australian Alopecia Areata Patients—Results From an Australian Expert Consensus Exercise
- Ritlecitinib: Efficacy of a Novel Therapy for Severe Alopecia Areata in Patients Aged 12 Years and Older